Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-16-015092
Filing Date
2016-11-14
Accepted
2016-11-15 15:04:36
Documents
58
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 1379805
2 ex31-1.htm EX-31.1 18881
3 ex31-2.htm EX-31.2 18743
4 ex32-1.htm EX-32.1 8155
5 ex32-2.htm EX-32.2 8297
  Complete submission text file 0001493152-16-015092.txt   8395481

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rspi-20160930.xml EX-101.INS 1415653
7 XBRL SCHEMA FILE rspi-20160930.xsd EX-101.SCH 95627
8 XBRL CALCULATION FILE rspi-20160930_cal.xml EX-101.CAL 54501
9 XBRL DEFINITION FILE rspi-20160930_def.xml EX-101.DEF 392898
10 XBRL LABEL FILE rspi-20160930_lab.xml EX-101.LAB 643099
11 XBRL PRESENTATION FILE rspi-20160930_pre.xml EX-101.PRE 466001
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16467 | Film No.: 161999350
SIC: 2834 Pharmaceutical Preparations